

Government Medical Store Depot Karnal
Medical Stores Organization
Directorate General of Health Services
Ministry of Health and Family welfare
Opposite Telephone Exchange,
Near Head Post Office, Karnal 132 001

Minutes of Pre-Bid Meeting

Subject E-tender for Conclusion of Rate Contract for 280 Group-A Generic drugs (Tender No. GMSDK/02/PS/01/Tender-01/Grp-A generic drugs/2026-27, Tender ID - 2026_DGHS_904225_4) published on CPPP Portal on 02/04/26

The Pre-bid meeting for E-tender for conclusion of Rate contract of 280 Group-A Generic Drugs through e-procurement portal <http://eprocure.gov.in/eprocure/app> (Two bid system. Technical Bid and Price Bid) was held on 11/04/26 at 11:00 AM at Govt. Medical Store Depot, Karnal under the chairpersonship of Dr. Anju Nanda, Dy. Director General (Stores), Medical Stores Organization, R.K. Puram, New Delhi.

The meeting was attended by the following officers: -

1. Dr. Binay Kumar, Chief Medical Officer (NFSG) I/c GMSD, Karnal
2. Sh. Lalit Kishor, Sr. Accounts Officer, GMSD, Karnal
3. Sh. Vinod Kumar, Depot Superintendent, GMSD, Karnal
4. Smt. Rita, Depot Superintendent, GMSD, Karnal
5. Smt. Shubha Niranjana, Pharmacist-cum-Clerk, GMSD, Karnal
6. Sh. Joginder Kumar, Stenographer, GMSD Karnal

At the outset, the Chairperson welcomed all participants and informed that all queries received through email and letters, as well as those raised during the meeting, would be duly examined. It was further informed that the clarifications issued during the pre-bid meeting shall form an integral part of the tender document.

All queries received were examined and consolidated under thematic areas. The decisions taken are in accordance with tender conditions, GFR 2017, and principles of transparency, fairness, and competition.

Thematic Clarifications & Decisions

All queries were examined and consolidated under thematic areas. No modification in eligibility criteria, warehouse requirements, delivery period, regulatory compliance, and technical specifications was considered necessary unless explicitly clarified. Certain operational relaxations and documentation clarifications have been allowed as detailed in the MOM.

A summary of bidder-wise queries and their disposition is placed at Annexure-I. Detailed clarifications have been issued in thematic form to ensure uniformity and transparency.

With regard to **eligibility criteria, including turnover requirements, mandatory warehouse conditions under Annexure-K, and requests for supply through distributors or C&F agents**, it was decided that no modification is warranted. The existing provisions have been framed to ensure reliable supply across all GMSDs, compliance

Shubha
11/4/26

Joginder
11/4/26

Lalit
11/4/26

Rita
11/4/26

Binay
11/4/26

Anju
11/4/26

with prescribed storage and distribution norms, and timely execution of supply orders. Accordingly, the requirement for maintaining warehouses in each GMSD jurisdiction shall remain unchanged, unless specified further and requests for centralized or zonal warehousing models arrangements are not admissible.

With reference to Annexure-K, GST Registration Certificate and last 3 months GST Returns of warehouse must be uploaded alongwith Drug license of warehouse location. In case of fresh application evidence of fee filing must be submitted. However GST Registration Certificate and license thereof must be submitted before 26th May, 2026.

On the issue of **delivery period**, several bidders requested extension from 45 days to 60 days citing API shortages and logistical challenges. After due consideration, the request was not accepted. The delivery period of 45 days, as stipulated in the tender, is retained since it is aligned with operational requirements of GMSD/CGHS and is critical to ensuring uninterrupted availability of medicines.

Regarding **regulatory compliance**, particularly in respect of **Fixed Dose Combinations (FDCs)**, it was clarified that CDSO/DCGI approval is mandatory wherever applicable. Bidders shall submit valid CDSO/DCGI approval certificates for FDC drugs at the time of bid submission, unless otherwise specified. No relaxation in regulatory requirements is permissible.

With respect to **technical specifications**, including composition, strength, nomenclature, and pharmacopoeial standards, requests for modifications were examined but not accepted. It is reiterated that the specifications provided in the **Schedule of Requirement (SOR)** are to be strictly adhered to, and no deviation in composition or strength is permitted until specified further.

In relation to **dosage forms**, it is clarified that **capsule and tablet forms, Injection and vial form** shall be treated at par, unless specifically restricted under applicable pharmacopoeial standards or statutory rules. **Value-added formulations** such as SR/CR/ER/XR/PR/MR etc. are acceptable and will be treated at par for evaluation purposes.

On the matter of **packing and pack size**, it is clarified that **larger pack sizes may be accepted** subject to rate equivalence with the pack size specified in the SOR. **Alternative pack sizes**, such as strip of 15 tablets or Caps. packs, may be considered provided all other tender conditions are complied with. **Rates shall be normalized appropriately on a per unit basis wherever required.**

Requests for **relaxation in shelf life** conditions, including acceptance of products with **lower shelf life** such as 18 months will **not be accepted** unless approved/specified by Drug Controller. The shelf-life criteria prescribed in the tender document shall remain unchanged and must be strictly complied with.

With regard to **documentation requirements**, it is clarified that Annual Turnover Certificates, Balance Sheets, and Profit & Loss Statements bearing valid UDIN shall be **accepted even if the tender ID is not mentioned**. However Annexure G, Annexure-H and Certificate of Local content Tender specific ID is required. Bidders are required to submit samples of primary packing except for injectable prior to tender opening as per tender conditions. Third-party manufacturing or marketing arrangements shall not be admissible where specifically restricted under the tender provisions.

Sharma
11/4/26

Jopendra
11/4/26

11/4/26

11/4/26

11/4/26

11/4/26

A specific operational relaxation was considered in respect of supply to Karnal GMSD from Zirakhpur (Mohali) warehouse. Considering geographical proximity (Satellite city) and operational feasibility, such supply shall be permitted. However, this relaxation is strictly case-specific and shall not be construed as a general waiver of the warehouse requirements prescribed under the tender.

Further, with regard to warehouse requirements, it is clarified that warehouses located within the National Capital Region (NCR) of Delhi shall be considered as meeting the requirement for GMSD New Delhi. Additionally, warehouses situated in locations falling within the common operational jurisdiction or geographical proximity of Delhi NCR and Haryana shall be considered valid for servicing both GMSD New Delhi and GMSD Karnal, subject to operational feasibility.

It is further informed that necessary corrections in item descriptions, including those identified during the pre-bid stage, shall be issued through a corrigendum on the CPP Portal.

Additional clarifications include that larger pack size of Bott. and Tube may be accepted subject to rate parity, and unit-based pricing shall be applicable wherever relevant. Existing Rate Contract holders may continue to supply medicines till the validity of their contracts. The roadmap for procurement cycle has already been communicated and is available on the DVDMS portal.

Further, with regard to registration of manufacturing units with MSO, it is clarified that bidders may submit provisional documents such as proof of application, including receipts or acknowledgements, at the time of bid submission. However, submission of the final valid registration certificate shall be mandatory by the stage of technical evaluation, i.e., on or before 26th May 2026, failing which the bid shall be treated as non-responsive and liable for rejection.

With respect to submission of Non-Conviction Certificate, it is clarified that the certificate should preferably be general in nature and not organization-specific or tender-specific. In case the certificate is organization-specific or tender-specific, it shall be considered valid only if it pertains specifically to this tender. Certificates issued for any other organization or bearing reference to any other tender shall not be considered acceptable. In cases where the validity period of the certificate is not explicitly mentioned, the same shall be treated as valid for a period of six months from the date of issue.

Annexure-J: BMR & API linkage form, duly filled, signed and stamped by Authorised Signatory must be uploaded. In view of the large size, BMR shall be required to be submitted on as and when required basis.

With reference to the Bill of Quantities (BOQ), it is clarified that the rate unit indicated as "1" shall be construed as the unit rate for the respective item. Accordingly, bidders are required to quote rates on a per unit basis, such as per tablet, capsule, bottle, tube, respule, inhaler, rotacap, respicap, kit, ampoule, vial, sachet, pre-filled syringe (PFS), oral dispersible strip (ODS), flexipen, cartridge, or any other applicable unit as per the item description.

With regard to submission of the tender document, it is clarified that in view of the large file size, bidders may submit the hard copy of complete tender document, duly signed and stamped by the Authorized signatory, along with the Integrity Pact as per the prescribed requirements. However, at the time of submission of bids,

Shruti
11/4/26

Topalwar
11/4/26

11/4/26

11/4/26

11/4/26

11/4/26

bidders shall mandatorily submit the first two pages and the last two pages of the tender document, duly signed and stamped, as a token of acceptance and for reference purposes.

It is clarified that provisions regarding Global Tender Enquiry (GTE) exemption shall be governed strictly as per the applicable provisions of GFR 2017 and the Public Procurement (Make in India) policy, as amended from time to time. No separate deviation is envisaged under this tender. If, any product not manufactured in India and it is imported then it must be in the GTE List.

Biological and Imported Items, which are acceptable on In House Test Report are exempted from submission of STP.

Data Logger should be provided by the firm if the cold chain item is delivered through road. In case of delivery through Air, data logger should be provided upto the time of packing and an undertaking must be submitted of valid period of required temperature. The item should be delivered at GMSDs within that period.

Samples of Strips of Tablet and Capsules for which bidders are participating will be deposited duly sealed by the firms alongwith Integrity pact.

Annexure-I

Summary of Bidder-wise Queries and their Disposition

Sl. No.	Name of Bidder	Brief Summary of Query	Disposition
1	M/s Theon Pharmaceuticals Ltd.	Requested for withdrawal of the mandatory clause of warehouse Maintaining separate warehouses clause to inadvertently favour small group of companies and exclusion of experienced and eligible suppliers, restricting fair competition in tender process, financial burden it may pose (GST), compliance with local regulations	Not admissible
2	M/s Bayer Pharmaceuticals Pvt. Ltd.	Requested for Relaxation of tender condition regarding warehouse in Karnal (Annexure-K) on account if having branch in Zirakpur (Dist. Mohali, Punjab)	Admissible for warehouse.
3	M/s Raptakos Brett & Co Ltd.	Requested for Relaxation of tender condition regarding warehouse in Karnal (Annexure-K) on account of having branch in Zirakpur (Dist. Mohali, Punjab)	Admissible

Shubhe
11/4/26
Jopendra
11/4/26

11/4/26

11/4/26

11/4/26

11/4/26

4	M/s Astonea	<ol style="list-style-type: none"> 1. Requested for maintaining previous turnover limits owing to the revision of turnover clause leading to their disqualification form participating in tender for group A. The firm is already registered up to 27/1/2031. 2. Requested for withdrawal of the mandatory clause of warehouse claiming it to be restrictive. 3. Restoration of 60-day delivery period instead of the revised 45 days owing to the time-intensive process of procurement and testing of API, production and quality control, sterility testing requiring 42 days, logistic transit. 	Not admissible
5	M/s DWD Pharma	Requested to grant waiver for Annexure K and the related qualification Criteria	Not admissible
6	M/s IPCA Laboratories	Amendment in pack size or allowing to participate despite Deviation from Pack size for 6 VMS items strip of 4, 15 and cap instead of tab	Admissible
7	M/s Synokem Pharma	<ol style="list-style-type: none"> 1. Relaxation in Annexure K-warehouse requirement to allow supply through authorized distributor. 2. Permission to participate with valid State Licensing Authority approvals along with DCGI-approved products 3. Extension of delivery period from 45 days to 60 days 4. Corrections in (10) VMS item description eg. Addition of SR, ER,PR, cap instead of Tab 	<p>Not admissible</p> <p>Not Admissible</p> <p>Not admissible</p> <p>Already addressed above.</p>
8	M/s Tasmed	<ol style="list-style-type: none"> 1. Requested for maintaining previous turnover limits owing to the revision of turnover clause leading to their disqualification. The firm is already registered up to 20/7/2027. 2. Requested for withdrawal of the mandatory clause of warehouse to encourage broader participation-Claimed that the requirement of warehoused in 7 states to be highly restrictive due to the cost 	<p>Not admissible</p> <p>Not Admissible</p>

Shubhe
11/4/26

Tapan
11/4/26

11/4/26

11/4/26

11/4/26

11/4/26

		implications, regulatory context (one nation one tax), entry barrier to MSME 3. Restoration of 60-day delivery period instead of the revised 45 days owing to the time-intensive process of procurement and testing of API, production and quality control, sterility testing requiring 42 days, logistic transit.	Not Admissible
9	M/s FDC Ltd.	Requested for amendment in shelf life, Requested for amendment in pack size	Not admissible Already addressed above.
10	M/s Preet Remedies Ltd.	1. Requested for maintaining previous turnover limits owing to the revision of turnover clause leading to their disqualification 2. Requested for withdrawal of the mandatory clause of warehouse claiming its cost implications, regulatory context & policy alignment w.r.t.MSMEs. 3. Restoration of 60-day delivery period instead of the revised 45 days owing to the time-intensive process of procurement and testing of API, production and quality control, sterility testing requiring 42 days, logistic transit	Not admissible Not admissible Not admissible
11	M/s Stadmed Pvt. Ltd.	1. Requested for maintaining previous turnover limits owing to the revision of turnover clause leading to their disqualification from participating in tender for group A despite being registered till 28-6-2027 2. Requested for withdrawal of the mandatory clause of warehouse claiming it to be restrictive. 3. Restoration of 60-day delivery period instead of the revised 45 days owing to the time-intensive process of procurement and testing of API, production and quality control, sterility testing requiring 42 days, logistic transit.	Not admissible Not admissible Not admissible

Shubhe
11/4/26

Jyoti
11/4/26

11/4/26

11/4/26

11/4/26

11/4/26

12	M/s Eris Life Sciences Ltd.	Requested for amendment of delivery period clause-extension from 45 days to 60days considering manufacturing of dedicated tender stocks, time required in procurement & packaging, QC and testing, packing, dispatch and logistics	Not admissible.
13	M/s logos Pharma	Requested for reconsideration w.r.t. following: 1. Mandatory warehouse in seven states owing to the economic impact and regulatory context 2. Reduced delivery timeline due to the time-consuming process of drug manufacturing, testing and delivery	Not admissible Not admissible
14	M/s Eli-lilly	Requested to amend 1. Annexure-K warehouse requirement 2. BMR requirement in Annexure J exemption for imported items 3. STP exemption for for imported products (inhouse and NABL test reports already being supplied) 4. Shelf-life relaxation for imported products 5. Delivery period relaxation (21 days consumed for NABL) 6. Data logger relaxation for supplies sent through air courier in special approved boxes	Not admissible As addressed above. As addressed above. Not Admissible Not Admissible As addressed above.
15	M/s Alcon Laboratories India Pvt. Ltd.	Inclusion of item in GTE list	As addressed above.
16.	M/s Macleods	Request for approval of pack size in 15 tab and 10 tab per strip both	As addressed above.
17	M/s Zydus Life Sciences	Requested for withdrawal of the mandatory clause of warehouse. Restoration of 60-day delivery period instead of the revised 45 days Annexure-J	Not admissible Not admissible As specified in Tender documents

Shubhe
11/4/26

Jeyashree
11/4/26

11/4/26

Rifa
11/4/26


11/4/26


11/4/26


18.	M/s Aglowmed Ltd	<ol style="list-style-type: none"> 1. Requested to amend 200cr turnover criteria for Group A -as it will lead to disqualification. 2. DCGI Permission for all FDC and new Drug Quoted claimed that the DCGI issues the Permission for any FDC for the 1st time, and after 4 years all the regional FDA's issues Permission to any Pharma Company.-Not required if already approved by DCGI 3. Annexure-J: Undertaking regarding Batch Manufacturing Record & API Linkage Form along with each and every supply is not feasible-additional burden of documentation. 4. Annexure-K-significant operational and financial challenges. Suggested that instead of mandating warehouses in each GMSD Depot location, the country may be divided into four operational zones, with the requirement for bidders to maintain at least one warehouse in each zone 5. Undertaking to provide STP along with supplies: requested to provide STP once-with every supply will create additional burden documentation. 	<p>Not admissible</p> <p>As addressed above</p> <p>As specified in Tender documents</p> <p>Not Admissible</p> <p>As specified in Tender document</p>
-----	------------------	--	--


These minutes, including all clarifications issued herein, shall form an integral part of the tender document. No further queries shall be entertained after issuance of these minutes.


The meeting concluded with a vote of thanks to the Chair.



(Shubha Niranjana)
PCC



(Joginder Kumar)
Stenographer


(Vinod Kumar)
Depot Supdt.


(Rita Sharma)
Depot Supdt.


(Lalit Kishor)
Sr. Accounts Officer


(Dr. Binay Kumar)
Chief Medical Officer (NFSG) I/c


(Dr. Anju Nanda)
Dy. Director General (Stores)
DGHS (MSO), R.K.Puram, New Delhi